Heart Failure Staging
On this page
Direct answer
Heart failure is staged by the ACC/AHA system into stages A to D — A: at risk with risk factors only; B: structural heart disease without symptoms; C: structural disease with current or previous symptoms; D: refractory failure needing advanced therapies — a one-way progression that guides therapy. The New York Heart Association (NYHA) classification grades symptoms from class I (no limitation) to class IV (symptoms at rest) and can fluctuate with treatment. Drug therapy for heart failure with reduced ejection fraction now rests on four pillars: an ARNI or ACE inhibitor, a beta blocker, a mineralocorticoid receptor antagonist and an SGLT2 inhibitor.
What you must remember
- The two systems contrasted: staging (A to D) reflects disease progression and cannot move backwards, while NYHA class (I to IV) reflects current symptoms and can improve or worsen.
- Stage A: hypertension, diabetes, obesity, cardiotoxin exposure — treat risk factors; Stage B: structural disease without symptoms — add ACE inhibitor or ARB and beta blocker; Stage C: symptoms — full guideline-directed therapy; Stage D: refractory symptoms — inotropes, transplant or palliation.
- Ejection fraction categories: reduced (HFrEF) 40 per cent or less, mildly reduced 41 to 49 per cent, preserved (HFpEF) 50 per cent or more — SGLT2 inhibitors benefit both reduced and preserved phenotypes.
- Four pillars of HFrEF therapy: angiotensin receptor-neprilysin inhibitor (or ACE inhibitor/ARB), an evidence-based beta blocker (bisoprolol, metoprolol succinate, carvedilol), a mineralocorticoid receptor antagonist (spironolactone, eplerenone) and an SGLT2 inhibitor (dapagliflozin, empagliflozin) — start low and titrate early, in any order.
- Diuretics relieve congestion but do not reduce mortality; loop diuretics are first choice for volume overload.
- Devices: cardiac resynchronisation therapy for symptomatic patients with wide QRS (especially 150 ms or more with left bundle branch block) and ejection fraction 35 per cent or below; an implantable cardioverter-defibrillator for ejection fraction 35 per cent or less despite three months of optimal therapy.
- Echocardiography is the single most useful investigation; natriuretic peptides help rule out heart failure in undifferentiated dyspnoea.
- Common causes in India: ischaemic heart disease, hypertension, rheumatic valve disease and cardiomyopathies.
One patient, both classification systems, then the prescription
A 66-year-old man with a prior anterior infarct now has an ejection fraction of 32 per cent and breathlessness climbing one flight. He is stage C by ACC/AHA — structural disease with current symptoms — and NYHA class II today; with better therapy the class may improve, but he remains stage C for life. That contrast is the whole point: staging is the one-way street guiding therapy (A risk factors; B structural disease without symptoms; C symptoms, full therapy; D refractory), while NYHA is the fluctuating gauge. The echocardiogram also phenotyped him — 40 per cent or less reduced, 41 to 49 mildly reduced, 50 or more preserved — and his reduced phenotype earns the four pillars, titrated early in any order: Loop diuretics relieve congestion without touching mortality. Symptomatic with ejection fraction 35 per cent or below and QRS 150 ms or more with left bundle branch block, resynchronisation follows; a defibrillator waits for 35 per cent or less despite three months of optimal therapy.
Where students slip
The staging-versus-NYHA distinction carries the marks: "a stage C patient improves from NYHA III to NYHA II" is true, while "he reverts to stage B" is the false statement the options plant. The second slip is the pillar count — older lists with three pillars predate the SGLT2 inhibitor. The device thresholds are perennial: And the preserved-ejection-fraction stem is answered with diuretics, comorbidity control and an SGLT2 inhibitor — reaching for the reduced-EF armamentum in HFpEF is the deliberate distractor.
Frequently asked questions
What are the ACC/AHA stages of heart failure?
A: risk factors only; B: structural disease without symptoms; C: structural disease with symptoms; D: refractory failure requiring advanced therapies.
How does NYHA classification differ from staging?
NYHA grades I to IV describe current symptoms and can improve with treatment, whereas ACC/AHA stages reflect disease progression and do not reverse.
What are the four pillars of HFrEF drug therapy?
An ARNI or ACE inhibitor, an evidence-based beta blocker, a mineralocorticoid receptor antagonist and an SGLT2 inhibitor.
Which device suits a wide-QRS patient with low ejection fraction?
Cardiac resynchronisation therapy, particularly with QRS 150 ms or more and left bundle branch block, alongside medical therapy.
What is the role of diuretics?
Symptomatic relief of congestion with loop diuretics first line — essential for comfort, but not proven to reduce mortality.
How is HFpEF managed?
Diuretics for congestion, aggressive control of hypertension, diabetes and atrial fibrillation, and an SGLT2 inhibitor to reduce hospitalisation.